Aeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Shares of AEZS opened at $8.00 on Wednesday. Aeterna Zentaris has a 1 year low of $5.44 and a 1 year high of $12.80. The company has a 50 day simple moving average of $8.05 and a two-hundred day simple moving average of $7.63. The firm has a market cap of $9.71 million, a P/E ratio of -0.59 and a beta of 1.60.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($4.64) EPS for the quarter, missing the consensus estimate of ($3.88) by ($0.76). The company had revenue of $0.12 million during the quarter. Aeterna Zentaris had a negative return on equity of 63.20% and a negative net margin of 368.01%.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.